Key Takeaways
Corcept Therapeutics (NASDAQ: CORT) will present new overall survival data from its pivotal Phase 3 ROSELLA trial for Lifyorli in platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting on May 29.
"The data will be presented in an oral presentation on Friday, May 29, 2026," the company said in a press release.
Lifyorli (relacorilant), taken in combination with nab-paclitaxel, was approved by the U.S. Food and Drug Administration in March 2026. It is the first selective glucocorticoid receptor antagonist approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatments.
The new data on overall survival is a critical metric for the drug's commercial launch, potentially influencing physician adoption and its competitive standing. Investors are watching to see if the data can expand on the drug's initial approval and support a pending European marketing application.
Lifyorli is an oral medication that modulates the effects of cortisol, a hormone that can help tumors resist chemotherapy. By selectively blocking the glucocorticoid receptor, Lifyorli is designed to enhance the tumor-killing effect of chemotherapy agents like nab-paclitaxel. It is the first FDA-approved drug with this mechanism for this indication.
The market for this treatment is significant. An estimated 20,000 women in the United States and a similar number in Europe are candidates for new therapy for platinum-resistant ovarian cancer each year.
The drug's label includes significant safety information. Lifyorli is contraindicated in patients receiving systemic glucocorticoids for life-saving purposes. Warnings and precautions include the risk of neutropenia (low white blood cells), adrenal insufficiency, and potential exacerbation of other conditions treated with glucocorticoids.
The most common adverse reactions seen in the trial (>20%) included decreased hemoglobin, decreased neutrophils, fatigue, nausea, and diarrhea. Serious adverse reactions occurred in 35% of patients, with fatal adverse reactions in 2.1% of patients in the combination arm.
The upcoming data will provide a more complete picture of Lifyorli's clinical profile. Investors will be watching the ASCO presentation on May 29 for results that could significantly impact Corcept's revenue outlook and its stock, which has been watched closely since the drug's approval.
This article is for informational purposes only and does not constitute investment advice.
